Supriya Lifescience Ltd.
Snapshot View

300.80 +1.80 ▲0.6%

07 October 2022, 04:01:00 PM
Volume: 19,291

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.supriyalifescience.com
Market Cap 2,420.92 Cr.
Enterprise Value(EV) 2,214.31 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 18.86 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 15.95 Trailing Twelve Months Ending 2022-03
Industry PE 31.91 Trailing Twelve Months Ending 2022-03
Book Value / Share 79.64 Trailing Twelve Months Ending 2022-03
Price to Book Value 3.78 Calculated using Price: 300.80
Dividend Yield 0.20 Period Ending 2022-03
No. of Shares Subscribed 8.05 Cr. 80,482,800 Shares
FaceValue 2
Company Profile
The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. The company has niche product offerings of various APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
+0.60%
1 Week
+0.28%
1 Month
-13.92%
3 Month
-12.29%
6 Month
-37.96%
1 Year
2 Year
5 Year
10 Year
9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 29.57 29.61 17.20 15.05 18.38 53.11 60.42 59.17 34.34
Return on Capital Employed (%) 19.43 15.83 12.27 11.48 13.80 36.52 49.67 60.12 43.34
Return on Assets (%) 5.42 5.37 2.80 2.40 3.59 15.82 24.90 31.61 25.73

Balance Sheet View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Shh. Funds 26 30 37 42 46 55 94 149 269 616
Non Curr. Liab. 11 17 23 39 51 45 24 32 31 19
Curr. Liab. 65 83 115 150 144 146 135 155 146 100
Minority Int.
Equity & Liab. 101 130 176 231 241 245 253 336 445 735
Non Curr. Assets 39 52 73 102 126 126 120 138 180 237
Curr. Assets 62 78 103 129 115 120 133 198 265 498
Misc. Exp. not W/O
Total Assets 101 130 176 231 241 245 253 336 445 735

Profit Loss View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Net Sales 92 113 138 171 184 213 278 312 391 530
Other Income 3 2 2 2 7 9 8 11 5 8
Total Income 95 115 140 173 191 222 286 323 396 538
Total Expenditure -81 -98 -121 -151 -166 -191 -213 -213 -218 -316
PBIDT 14 16 20 22 25 31 73 109 178 222
Interest -5 -6 -7 -10 -12 -11 -10 -7 -4 -4
Depreciation -2 -2 -2 -4 -5 -5 -5 -6 -7 -10
Taxation -3 -2 -2 -2 -2 -6 -18 -23 -44 -55
Exceptional Items
PAT 5 6 8 6 6 9 39 73 124 152
Adjusted EPS 10 13 17 4 4 6 27 50 17 19

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. -6 14 27 28 49 116 76 49
Cash Fr. Inv. -23 -33 -27 -5 5 -25 -47 -60
Cash Fr. Finan. 30 21 -2 -20 -50 -29 -15 150
Net Change 1 2 -2 3 4 62 15 139
Cash & Cash Eqvt 5 7 6 9 12 75 89 228

Shareholding Pattern View Details >>

3 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%)
Promoter 68.24 68.24 68.24
Public 31.76 31.76 31.76
Depository Receipts 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00

Announcements View Details >>

Mon, 03 Oct 2022
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Pursuant to the relevant provisions of the SEBI Listing Regulations we are enclosing herewith Press Release for Appointment of Mr. Rajeev Kumar Jain as Chief Executive Officer & Key Managerial Personnel w.e.f. October 3 2022.
Thu, 29 Sep 2022
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the relevant provisions of the SEBI Listing Regulations we would like to inform you that the officials of our Company Supriya Lifescience Limited (Company) will be interacting with Analyst/Institutional Investors on September 29 2022 via video conference.
Thu, 29 Sep 2022
Closure of Trading Window
In accordance with the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015 as amended from time to time and the Companys Code of Conduct to Regulate Monitor and Report Trading in Securities by Insiders (hereinafter referred to as the "Prohibition of Insider Trading Code") the Trading window for dealing in the Securities of the Company for all the Insiders Designated Persons (including their immediate relatives) as defined in the Code shall remain closed from October 01 2022 till the expiry of 48 hours after the declaration of the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2022.

Technical Scans View Details >>

Thu, 06 Oct 2022
Opening at Low Opening at Low
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
High Decrease 1 Month High Decrease 1 Month
High Decrease 3 Months High Decrease 3 Months
High Decrease 6 Months High Decrease 6 Months

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 228,656.62 953.00 -0.1%
Divi's Laboratories Ltd. 99,250.74 3,738.70 +0.0%
Cipla Ltd. 91,332.41 1,131.75 -0.2%
Dr. Reddy's Laboratories Ltd. 72,821.94 4,372.95 -0.6%
Apollo Hospitals Enterprise Ltd. 63,207.02 4,395.95 +0.1%
Torrent Pharmaceuticals Ltd. 53,000.56 1,566.00 -2.3%
Zydus Lifesciences Ltd. 42,689.71 421.75 -0.3%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-06 58.79 953.00 -0.1%
Divi's Laboratories Ltd. Consolidated 2022-06 31.96 3,738.70 +0.0%
Cipla Ltd. Consolidated 2022-06 36.70 1,131.75 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-06 24.35 4,372.95 -0.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-06 71.55 4,395.95 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-06 66.17 1,566.00 -2.3%
Zydus Lifesciences Ltd. Consolidated 2022-06 9.66 421.75 -0.3%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-06 4.56 953.00 -0.1%
Divi's Laboratories Ltd. Consolidated 2022-06 7.98 3,738.70 +0.0%
Cipla Ltd. Consolidated 2022-06 4.25 1,131.75 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-06 3.60 4,372.95 -0.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-06 10.64 4,395.95 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-06 8.29 1,566.00 -2.3%
Zydus Lifesciences Ltd. Consolidated 2022-06 2.54 421.75 -0.3%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.02 953.00 -0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,738.70 +0.0%
Cipla Ltd. Consolidated 2022-03 0.04 1,131.75 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,372.95 -0.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,395.95 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,566.00 -2.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 0.25 421.75 -0.3%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 953.00 -0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,738.70 +0.0%
Cipla Ltd. Consolidated 2022-03 13.10 1,131.75 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,372.95 -0.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,395.95 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,566.00 -2.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 421.75 -0.3%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 953.00 -0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,738.70 +0.0%
Cipla Ltd. Consolidated 2022-03 13.10 1,131.75 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,372.95 -0.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,395.95 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,566.00 -2.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 421.75 -0.3%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 953.00 -0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,738.70 +0.0%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,131.75 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,372.95 -0.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,395.95 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,566.00 -2.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 15,265.20 421.75 -0.3%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 953.00 -0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,738.70 +0.0%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,131.75 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,372.95 -0.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,395.95 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,566.00 -2.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 2,326.40 421.75 -0.3%

FAQ's On Supriya Lifescience Ltd.

What is Supriya Lifescience share price?

Can I buy Supriya Lifescience shares now?

What is the Dividend Yield of Supriya Lifescience?

What is the Market Cap of Supriya Lifescience?

What are the key metrics to analyse Supriya Lifescience?

What is the 52 Week High and Low of Supriya Lifescience?

What is the trend of Supriya Lifescience share price?